Ardea Biosciences Inc

Ardea Biosciences — Corporate Update (March 2009)

37 slides from Ardea Biosciences's corporate update, Mar 16, 2009

  1. Slide 1: Company Update

    March 16, 2009 Company Update Barry D. Quart, PharmD President & Chief Executive Officer

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results

  3. Slide 3: Investment Highlights

    Investment Highlights Addressing multi-billion-dollar markets HIV Cancer Gout Inflammation Efficacy results in gout program will be presented at Analyst/Investor Day in New York in April – Phase 1 results with RDEA594 – Phase 2a results with RDEA806 Anticipate initiation of Phase 2 with RDEA594 in 2

  4. Slide 4: Pipeline Addresses Major Markets

    Pipeline Addresses Major Markets Discovery Preclinical Phase 0/1 Phase 2 Phase 3 A B RDEA806 Gout RDEA594 Gout 2 rd Gen URAT1 Gout RDEA806 NNRTI for HIV RDEA427 NNRTI for HIV RDEA119 MEKI for Cancer RDEA119 MEKI + sorafenib for Cancer RDEA119/ Inflammation RDEA436

  5. Slide 5: Gout

    GOUT Ardea Biosciences

  6. Slide 6: RDEA806 Significantly Reduced Serum Uric Acid in Phase 1 MAD Study

    RDEA806 Significantly Reduced Serum Uric Acid in Phase 1 MAD Study 1 Placebo 500 mg bid 0.5 400 mg MR bid 300 mg bid 0 Serum UA reduction in 2 - -0.5 patients with hyperuricemia ge in SUA -1 was the largest mg/dL)in the study; on ( Chan -1.5 the last day of *dosing, every * patient met the - -2 * *

  7. Slide 7: Hyperuricemia/Gout — Unmet Medical Need

    Hyperuricemia/Gout — Unmet Medical Need Gout is caused by abnormally elevated levels of uric acid (>6.8 mg/dL) Painful and debilitating disease – Attacks of severe pain/Inflammation – Disfiguring nodules (tophi) Kidney damage (nephropathy) Increasing incidence and severity in U.S. (over 5,000,000 pa

  8. Slide 8: Linear Relationship Between Serum Uric Acid and CRP

    Linear Relationship Between Serum Uric Acid and CRP NHANES III & NHANES 1999-2002 Linear dose-response pattern between sUA and logCRP for sUA concentrations above 4 mg/dL Upper 95% CI (mg/dL) p < 0.001 Log CRP Lower 95% CI NHANES III n = 18,723 NHANES 99-2002 n = 7,401 Serum Uric Acid (mg/dl) 2007 A

  9. Slide 9: Allopurinol Produced Blood Pressure Reductions in Adolescents with Hypertension

    Allopurinol Produced Blood Pressure Reductions in Newly Diagnosed Adolescents with Hypertension Randomized, double-blind, placebo-controlled, crossover trial involving 30 adolescents (aged 11-17 years) who had newly diagnosed, never-treated stage 1 essential hypertension and hyperuricemia. Results F

  10. Slide 10: Competitive Landscape

    Competitive Landscape Allopurinol – 40 year old generic xanthine oxidase inhibitor; 21% response rate and 8% SAEs in contemporary study, 1 and 0.4% incidence of hypersensitivity, which is 20-25% fatal 2 Febuxostat (ULORIC ® Takeda) – Approved by FDA in February 2009 in US for chronic gout management

  11. Slide 11: Transporters Found in Kidney Proximal Tubule Cells

    Transporters Found in Kidney Proximal Tubule Cells Multiple transporters play important roles in uric acid transport and the occurrence of gout – URAT1 previously identified as the most important transporter for uric acid – Mutations in ABCG2, SLC17A3, and SLC2A9 recently identified as linked to a h

  12. Slide 12: RDEA594, a Metabolite of RDEA806, Responsible for Uric Acid Lowering

    RDEA594, a Metabolite of RDEA806, is Believed to be Responsible for Uric Acid Lowering ~100% of uric acid is initially filtered through glomerular filtration RDEA594 URAT1 <99% Proximal Tubule Reabsorption Secretion (~50%) Reabsorption (~10% fine tuning) Increased Excretion Enomoto; Urat1 identifica

  13. Slide 13: RDEA594 Shows Dose Proportional Increases in AUC and Cmax

    RDEA594 Shows Dose Proportional Increases in AUC and Cmax Following Single Oral Doses 200 AUC 30 Cmax 160 25 g/ml) 120 20 (hr*u (ug/ml) AUClast 15 80 Cmax 10 40 Fed 5 Fed 0 0 0 200 400 600 0 200 400 600 Dose (mg) Dose (mg) Fed condition: 100, 400, 600 mg Fasting condition: 25, 100, 200 mg

  14. Slide 14: Mean Change in 24-Hour Serum Uric Acid After Single Doses

    Mean Change in 24-Hour Serum Uric Acid After Single Doses of RDEA594 and Comparators in NHV +10 %) 100 0 ( Baseline - -10 vs -20 C AU 100 100 sUA -30 70 fasted fed in ange - -40 Ch - -50 50 Mean 800 25 100 200 400 600 10 20 40 80 RDEA806 RDEA594 Benzbromarone EC Tab. Sol. Uric acid lowering increase

  15. Slide 15: RDEA594 Phase 2 Evaluations During 2009

    RDEA594 Phase 2 Evaluations During 2009 Phase 2 Dose Response, Safety & Efficacy Study – Three doses of RDEA594 compared to allopurinol/placebo Renal Impairment and Pharmacodynamic Study of RDEA594 – Safety, tolerability, pharmacokinetics, and impact on sUA in subjects with various degrees of renal

  16. Slide 16: RDEA594 Phase 2 Dose Response, Safety & Efficacy Study

    RDEA594 Phase 2 Dose Response, Safety & Efficacy Study Population: · gout patients with hyperuricemia (serum uric acid 8 mg/dL) • total of 180 patients in 5 treatment arms Duration: 8 wks: 2-wk run-in, 4-wk treatment, 2-wk follow-up Endpoint: Proportion of subjects with sUA level < 6.0 mg/dL at Day

  17. Slide 17: RDEA594: Lead Product Candidate for Gout

    RDEA594: Lead Product Candidate for Gout RDEA594 inhibits the URAT1 renal transporter, without significant effects on other renal transporters (no clinically significant interactions with OAT1 & OAT3), and it has no antiviral activity at target levels RDEA594 is a metabolite of RDEA806 in man and al

  18. Slide 18: HIV

    HIV Ardea \ Biosciences

  19. Slide 19: RDEA806 vs. Target Product Profile

    RDEA806 vs. Target Product Profile From preclinical through Phase 2a results to-date, RDEA806 appears to be a good candidate to meet the desired Target Product Profile Highly active against efavirenz-resistant strains High genetic barrier to resistance Better safety profile than efavirenz Reduced CN

  20. Slide 20: HIV Infection Demographics Support Target Product Profile

    HIV Infection Demographics Support Target Product Profile 20 *Estimates Out of 56,300 New Cases in 2006; CDC, New Estimates of HIV Infections

  21. Slide 21: RDEA806 Phase 2a Median Change in Viral Load

    RDEA806 Phase 2a Median Change in Viral Load* 0.5 Last Dose Placebo 0.0 0 5 10 15 20 400 mg BID Days 600 mg QD -0.5 800 mg QD 1000 mg QD -1.0 Percent Patients > 1 log Decrease < 400 copies/ml -1.5 Placebo 0 0 400 mg BID Capsules — Fasted 100% 56% -2.0 600 mg QD Capsules — Fasted 78% 33% 800 mg QD Ta

  22. Slide 22: RDEA806 Safety and Tolerability

    RDEA806 Safety and Tolerability No serious adverse events or premature discontinuations Adverse events generally mild (grade 1) with no required intervention; no grade 3/4 adverse events No indication of CNS toxicity and no drug related rash No clinically significant laboratory abnormalities No appa

  23. Slide 23: Tablet Size Comparisons of Coformulated RDEA806

    Tablet Size Comparisons of Coformulated RDEA806 RDEA806 800 mg RDEA806 600 mg ATRIPLA™ SUSTIVA ® INTELENCE™ RDEA806 + + Sustiva 600 mg 600 mg 100 mg 200 mg TRUVADA ® TRUVADA ® + Truvada ® 23

  24. Slide 24: No Impact of RDEA806 on Emtricitabine or Tenofovir in Truvada

    No Impact of RDEA806 on Emtricitabine or Tenofovir in Truvada Time-Concentration Profiles in Plasma Emtricitabine Tenofovir 1.8 g/mL) 0.25 1.6 /mL) 1.4 0.20 (µ 1.2 (µg entration ntration 0.15 1.0 0.8 0.10 0.6 Conc Conce 0.4 0.05 0.2 0.00 0.0 0 6 12 18 24 30 36 42 48 54 60 66 72 0 6 12 18 24 30 36 42

  25. Slide 25: RDEA427 Has Superior Resistance Profile to Other NNRTIs

    RDEA427 Has Superior Resistance Profile to Other NNRTIs 160 r Wt 120 e 80 ld Change ov 40 o F RDEA427 0 IDX899 TMC278 Etravirine Different structural class than RDEA806 Lower protein shift than other NNRTIs and broad spectrum coverage of resistant strains Based on an iv micro-dosing study in humans:

  26. Slide 26: Cancer and Inflammation

    Cancer and Inflammation Ardea \ Biosciences

  27. Slide 27: The Age of Targeted Cancer Treatments

    The Age of Targeted Cancer Treatments GF Herceptin, Erbitux RTK Tarceva Proliferation Ras Angiogenesis Differentiation Raf Nexavar Apoptosis ARRY-142886 (Ph 2) MEK XL518 (Ph 1) RDEA119 (Ph 1)* c-Myc Bcl-2 c-Jun Elk-1 Mcl-1 PDE4 cPLA2 ERK2 ERK2 MNK1/2 MAPKAPK1/3 27 *Only MEK inhibitor in clinic witho

  28. Slide 28: RDEA119 is Potent, Highly Specific MEK Inhibitor

    RDEA119 is Potent, Highly Specific MEK Inhibitor MEK1/2 Enzyme IC50 17-50 nM Cellular pERK EC50 2.5-8.7 nM* >100-fold selectivity in kinase panel of 205 enzymes at 10 µM** MEK1 & MEK2 MEK1 & MEK2 100 100 80 80 Inhibition 60 60 Ron % 40 40 SRC 20 20 0 0 1 1 6 6 11 11 16 16 21 21 26 26 *Cell lines: Co

  29. Slide 29: Hepatoma Cells Exhibit Resistance to Sorafenib

    Hepatoma Cells Exhibit Resistance to Sorafenib –RDEA119 is Highly Active as a Single Agent h Range of clinical levels ll Deat ent Ce c Per HUH7 29 March 2009 Confidential Presentation to TOP

  30. Slide 30: Sorafenib-Resistant Hepatoma Cells Show Response to Combination Therapy

    Sorafenib-Resistant Hepatoma Cells Show Remarkable Response to Combination Therapy ath e ent Cell D c Per 30

  31. Slide 31: RDEA119 and Gemcitabine Synergistically Inhibit Growth of Cancer Lines

    RDEA119 and Gemcitabine Synergistically Inhibit Growth of Human Cancer Lines Points below the isobolic line Indicate a synergistic interaction A549 NSCLC Cells MiaPaCa-2 – Pancreatic cancer 3 0.2 0.18 2.5 0.16 0.14 2 bine (µM) 0.12 Series2 19 (µM) Gemcita 0.1 Series1 RDEA1 1.5 0.08 0.06 1 0.04 Serie

  32. Slide 32: RDEA119 Synergistic in Combination with Many Other Anti-Cancer Agents

    RDEA119 Synergistic in Combination with Many Other Anti-Cancer Agents Potential Combinations Potential Therapeutic Areas Sorafenib Onyx/Bayer HCC Melanoma Gemcitabine Lilly Breast Myeloma Temozolomide Schering Pancreas Renal carcinoma Lapatinib GSK NSCLC Thyroid AKT inhibitors Merck, Others Colon RD

  33. Slide 33: RDEA119-101 Concentration-Time Profiles at Steady State

    RDEA119-101 Concentration-Time Profiles at Steady State Shaded target plasma levels produced 3000 optimal efficacy in xenograft studies Daily Dose (mg) 1000 100 60 40 30 100 20 10 6 10 4 2 1 0 2 4 6 8 10 12 14 16 18 20 22 24 Time (hr)

  34. Slide 34: RDEA119 is Active in Multiple Models of Inflammatory Disease

    RDEA119 is Active in Multiple Models of Inflammatory Disease Rat paw edema model Collagen-induced arthritis in mice and rats (2008 EULAR) Adjuvant-induced Arthritis (2008 EULAR) Pristane-induced arthritis in rats (2008 EULAR) Monosodium urate crystal (uric acid) induced inflammation (2008 ACR) Trini

  35. Slide 35: Financial Position Summary

    Financial Position Summary Statement of 17.9 million common Twelve Months shares outstanding Operations Ended (In thousands, except per share Dec. 31, 2008 data) 2008 cash usage* was $46.8 million – in line with guidance of $45 — $50 Revenue $ 304 million Operating expenses 56,779 Interest and other

  36. Slide 36: Near-Term Anticipated Milestones

    Near-Term Anticipated Milestones Drug Candidate Event Date Gout RDEA594 Phase 1 results 1Q09* RDEA806 Phase 2 results (PoC) 1Q09* RDEA594 Phase 2 start 2Q09 RDEA594 Phase 2 results 4Q09 2nd Gen URAT1 Inhibitor Clinical Candidate Selection 1H09 *Studies on schedule; data will be presented at Analyst/

  37. Slide 37: Ardea Biosciences

    1OSCIENCES Designing Solutions for Serious Diseases NASDAQ: RDEA

Ardea Biosciences — Corporate Update (March 2009) on 6ix